Status:
RECRUITING
Efficacy of Dorso-lateral Prefrontal Cortex Stimulation by tDCS in Motor Conversion Disorder Patients
Lead Sponsor:
Centre Hospitalier Universitaire de Nīmes
Conditions:
Conversion Disorder
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
Conversion disorder refers to impaired voluntary motor or sensory functions that are not compatible with a well-known neurological condition. This disorder affects up to 30% of hospitalized patients i...
Detailed Description
Conversion disorder, also called "functional neurological disorder" (DSM-5), refers to impaired voluntary motor or sensory functions that are not compatible with a well-known neurological condition. T...
Eligibility Criteria
Inclusion
- The patient must have given his/her informed and signed consent.
- The patient is at least (≥) 18 years old and 65 years old at the most (≤). The risk of an increased frequency of somatic comorbidity, drug co-prescription, and cognitive impairment prompts us to limit recruitment to age 65 in this study.
- The patient is hospitalized or followed in consultation.
- Patient is available for a follow-up of 6 months.
- With current DSM-5 criteria for conversion disorder during more than 10 days, motor type (i.e. with paralysis or motor weakness) and initial EDSS score ≥ 3 or initial WHO Score is ≥ 2
Exclusion
- The patient is participating in another interventional trial.
- The patient refuses to sign the consent.
- It is impossible to correctly inform the patient.
- The patient is pregnant or breastfeeding.
- Specialized neurological clinical examination and the performing of brain and medullary MRI reveal an organic neurological involvement.
- Current episode of mania, hypomania, diagnosis of substance abuse/dependence (excluding smoking), diagnosis of schizophrenia over lifetime, severe neurological pathology (epilepsy, stroke, brain tumor).
- Patient with a contraindication to MRI (for patients enrolled in Nîmes).
- Acute eczema at the electrodes loci.
Key Trial Info
Start Date :
March 5 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2025
Estimated Enrollment :
96 Patients enrolled
Trial Details
Trial ID
NCT04097184
Start Date
March 5 2021
End Date
September 1 2025
Last Update
February 13 2025
Active Locations (8)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre Hospitalier Universitaire
Nîmes, Gard, France, 30029
2
Hôpital La Colombière Service de Psychiatrie
Montpellier, Hérault, France, 34090
3
CHU de Montpellier Hôpital Gui De Chauliac Service de Neurologie
Montpellier, Hérault, France, 34295
4
Hôpital Lapeyronie
Montpellier, Hérault, France, 34295